Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 14/20 | 0.45 |
| ▸ | MTOR | P42345 | 14/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 12/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 12/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.45 |
| ▸ | BMI1 | P35226 | 3/20 | 0.41 |
| ▸ | DHFR | P00374 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16740735 | 0.90 | PIK3CA (0.44) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL16748426 | 0.89 | BMI1 (0.44) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL16748487 | 0.86 | BMI1 (0.46) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL16740753 | 0.85 | PIK3CD (0.53) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL16550096 | 0.84 | BMI1 (0.50) | PIK3CAMTORBMI1DHFRMEN1 | |
| SCHEMBL15747614 | 0.84 | BMI1 (0.40) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL16748427 | 0.84 | MAPK1 (0.38) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL16748482 | 0.83 | BMI1 (0.48) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL16740776 | 0.82 | BMI1 (0.59) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL16740773 | 0.81 | PIK3CA (0.53) | PIK3CAMTORPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975878-B2 | Substituted triazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2018-05-22 | — | — | US | claimed |
| US-20160297798-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-10-13 | — | — | US | claimed |
| US-9975878-B2 | Substituted triazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975878-B2 | Substituted triazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20160297798-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-10-13 | — | — | US | disclosed |
| US-20160297798-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-10-13 | — | — | US | disclosed |
| WO-2015076801-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297798-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | BMI1, BAZ2A, BAZ2B | PIK3CA 3534/4885MTOR 3440/4885PIK3CD 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.